Lv43
782 积分 2024-08-19 加入
SMARCA4 alterations in non-small cell lung cancer: a systematic review and meta-analysis
1天前
待确认
SMARCA4 alterations in non-small cell lung cancer: a systematic review and meta-analysis
1天前
已完结
SMARCA4: Promises and challenges in the treatment of cancers
2天前
已完结
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
7天前
已完结
From cabozantinib to zanzalintinib: obvious chemical modifications as a new frontier in product hopping
8天前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
9天前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
9天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial
2个月前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
